Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
Recruiting
Phase 2
Interventional Study
Atherosclerosis Cardiovascular Disease
ASCVD
ASCVD Management
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 200 (estimated)
- Sponsor
- Atom Therapeutics Co., Ltd · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Unless otherwise specified, subjects must meet all of the following criteria at screening:
* Diagnosed with coronary at herosclerosis, and coronary angiography.
* Male or female at 18-75 years of age (inclusive).
* Weight ≥40 kg.
* Currently using any oral lipid-lowering therap…
Contacts